Brokerages Set Humana Inc (NYSE:HUM) Target Price at $339.00

Shares of Humana Inc (NYSE:HUM) have received a consensus rating of “Buy” from the twenty brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $338.11.

HUM has been the topic of a number of recent analyst reports. SunTrust Banks lifted their price objective on Markel to $1,100.00 and gave the stock a “hold” rating in a research report on Thursday, May 2nd. ValuEngine upgraded Valmont Industries from a “sell” rating to a “hold” rating in a research note on Friday. Credit Suisse Group reiterated a “buy” rating and set a $19.50 price objective on shares of Infineon Technologies in a research note on Thursday, May 2nd. Oppenheimer lowered their price objective on Littelfuse from $215.00 to $210.00 and set an “outperform” rating for the company in a research note on Thursday, May 2nd. Finally, Citigroup cut BCE from a “buy” rating to a “neutral” rating in a research note on Thursday, May 2nd.

Shares of NYSE:HUM traded down $1.02 during midday trading on Tuesday, hitting $284.30. 779,888 shares of the stock were exchanged, compared to its average volume of 1,344,268. The firm has a market cap of $39.33 billion, a PE ratio of 19.54, a price-to-earnings-growth ratio of 1.20 and a beta of 0.87. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.65 and a quick ratio of 1.65. The business’s 50-day simple moving average is $260.71. Humana has a 12 month low of $225.65 and a 12 month high of $355.88.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 EPS for the quarter, topping the Zacks’ consensus estimate of $4.30 by $0.18. Humana had a return on equity of 20.77% and a net margin of 2.99%. The company had revenue of $16.11 billion for the quarter, compared to analyst estimates of $15.67 billion. During the same period in the previous year, the firm earned $3.36 earnings per share. The firm’s quarterly revenue was up 12.8% on a year-over-year basis. Research analysts forecast that Humana will post 17.48 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.55 dividend. The ex-dividend date is Thursday, June 27th. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. Humana’s payout ratio is 15.12%.

Several large investors have recently bought and sold shares of HUM. Cornerstone Advisors Inc. raised its position in Humana by 13.5% during the second quarter. Cornerstone Advisors Inc. now owns 353 shares of the insurance provider’s stock valued at $94,000 after purchasing an additional 42 shares during the period. IFM Investors Pty Ltd grew its stake in shares of Humana by 7.9% during the second quarter. IFM Investors Pty Ltd now owns 9,977 shares of the insurance provider’s stock valued at $2,647,000 after buying an additional 728 shares during the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Humana by 0.6% during the second quarter. Oregon Public Employees Retirement Fund now owns 14,441 shares of the insurance provider’s stock valued at $3,831,000 after buying an additional 84 shares during the last quarter. Beech Hill Advisors Inc. bought a new position in shares of Humana during the second quarter valued at approximately $1,063,000. Finally, Unigestion Holding SA grew its stake in shares of Humana by 14.8% during the second quarter. Unigestion Holding SA now owns 303,121 shares of the insurance provider’s stock valued at $80,418,000 after buying an additional 39,008 shares during the last quarter. Institutional investors own 92.51% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: Why Invest in Dividend Achievers?

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit